Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Innoviva, Inc. (INVA : NSDQ)
 
 • Company Description   
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.

Number of Employees: 101

 
 • Price / Volume Information   
Yesterday's Closing Price: $11.25 Daily Weekly Monthly
20 Day Moving Average: 879,340 shares
Shares Outstanding: 69.78 (millions)
Market Capitalization: $785.06 (millions)
Beta: 0.56
52 Week High: $20.71
52 Week Low: $10.64
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 2.93% -0.28%
12 Week -14.19% -20.48%
Year To Date -15.09% -20.24%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1350 OLD BAYSHORE HIGHWAY SUITE 400
-
BURLINGAME,CA 94010
USA		 ph: 650-238-9600
fax: 650-827-8690		 investor.relations@inva.com http://www.inva.com
 
 • General Corporate Information   
Officers
Pavel Raifeld - Chief Executive Officer
George Bickerstaff - Chairman
Marianne Zhen - Chief Accounting Officer
Odysseas Kostas - Director
Mark DiPaolo - Director

Peer Information
Innoviva, Inc. (AGN.)
Innoviva, Inc. (ABBV)
Innoviva, Inc. (NVO)
Innoviva, Inc. (LLY)
Innoviva, Inc. (RHHBY)
Innoviva, Inc. (JNJ)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: Large Cap Pharma
Sector: Medical
CUSIP: 45781M101
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 12/01/22
Next Expected EPS Date: 04/26/23
Share - Related Items
Shares Outstanding: 69.78
Most Recent Split Date: (:1)
Beta: 0.56
Market Capitalization: $785.06 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $0.33 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $1.37 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: 0.00
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 04/26/23  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 8.21
Trailing 12 Months: 8.52
PEG Ratio: -
Price Ratios
Price/Book: 1.39
Price/Cash Flow: 4.84
Price / Sales: 2.37
EPS Growth
vs. Year Ago Period: -54.55%
vs. Previous Quarter: -58.33%
Sales Growth
vs. Year Ago Period: -38.89%
vs. Previous Quarter: -2.16%
ROE
03/31/23 - 18.81
12/31/22 - 23.89
09/30/22 - 28.86
ROA
03/31/23 - 9.10
12/31/22 - 12.13
09/30/22 - 15.19
Current Ratio
03/31/23 - 3.29
12/31/22 - 2.77
09/30/22 - 3.18
Quick Ratio
03/31/23 - 2.87
12/31/22 - 2.34
09/30/22 - 3.18
Operating Margin
03/31/23 - 32.99
12/31/22 - 36.57
09/30/22 - 38.16
Net Margin
03/31/23 - 64.56
12/31/22 - 78.39
09/30/22 - 24.64
Pre-Tax Margin
03/31/23 - 86.60
12/31/22 - 109.35
09/30/22 - 60.64
Book Value
03/31/23 - 8.11
12/31/22 - 9.19
09/30/22 - 8.11
Inventory Turnover
03/31/23 - 0.44
12/31/22 - 0.21
09/30/22 - -
Debt-to-Equity
03/31/23 - 0.79
12/31/22 - 0.69
09/30/22 - 0.78
Debt-to-Capital
03/31/23 - 43.98
12/31/22 - 40.89
09/30/22 - 43.94
 

Powered by Zacks Investment Research ©